Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Researchers at the University of Alberta looked at conversations between pharmacists and patients before and after an ...

We recently made a list of UBS’ Best Stocks In The AI, Growth & Low Rates Era: Top 29 US Stocks. In this piece, we will take ...

The CDC’s Advisory Committee on Immunization Practices is recommending that the age for pneumococcal vaccination be lowered to 50 years.

While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional ...

Merck reports Q3 sales of $16.7 billion, up 4% year-over-year, with Keytruda revenue rising 17%. EPS beats estimates; 2024 guidance updated on global demand shifts.

Pneumococcal shot recommendations are sometimes called the most complicated vaccination guidance that the government issues.

New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.

U.S. health officials last week recommended that people 50 and older get a shot against bacteria that can cause pneumonia and ...

A key panel of U.S. health advisers voted in favor of lowering the age recommendation for vaccines made by Pfizer Inc. and Merck & Co. that protect against pneumococcal disease, clearing a path ...

Capvaxive is Merck’s approved 21-valent pneumococcal conjugate vaccine indicated for active immunization for the prevention of invasive disease and pneumonia in adults 18 years of age and older.

The ACIP recommends vaccination for all adults aged 50 years and older who have not previously received a pneumococcal conjugate vaccine or whose ... medical officer, Merck Research Laboratories ...